COMPASS Pathways plc
NASDAQ:CMPSMedical - Care Facilities
+$0.02 today
- Market cap
- $1.15B
- Beta
- 2.51
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$1.63
Volume 2.35M
Average 4.09M
CMPS Net Income
Bottom-line profit, the starting point for calculating cash from operations.
COMPASS Pathways plcNASDAQ: CMPS
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns positive
Q1 FY2026 net income was $91.2M, compared with -$17.86M a year earlier. Trailing-twelve-month net income was -$178.8M. Over 3 fiscal years it compounded at +46.5% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$68.62M (-76.2%) for the fiscal year ending Dec 2026, a slowdown from the +85.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $91.2M+197.1% QoQ
- Last fiscal yearDec 2025
- -$287.86M+85.6% YoY
- LTMMar 2026
- -$178.8M+29.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +610.5% | -5.8% | -616.3 pp |
| 1 year | +85.6% | -76.2% | -161.7 pp |
| 3-year CAGR | +46.5% | -36.8% | -83.3 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (287.86M) USD
- Year-over-year change
- -85.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (287.86M) | -85.6% |
| FY2024 | 2024-12-31 | (155.12M) | -30.9% |
| FY2023 | 2023-12-31 | (118.46M) | -29.5% |
| FY2022 | 2022-12-31 | (91.51M) | -27.5% |
| FY2021 | 2021-12-31 | (71.74M) | — |
Net Income vs competitors
How CMPS compares with its peers on the latest reported figures
- CMPS's LTM Mar 2026 net income of $178.8M is the 8th largest of the 11 companies compared; the peer median is $153.38M.
- Its year-over-year change of +29.8% is the 7th highest of 9, against a peer median of +34.3%.
- Over three fiscal years its annual growth of +46.5% compares with a peer median of +29.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $108.22B | — | +109.1% | — | |
| LTM Jun 2026 | $511.45M | +6.8% | +16.3% | 14191.2% | |
| LTM Jun 2026 | $384.12M | +72.9% | — | 33.7% | |
| LTM Sep 2026 | $359.43M | +31.6% | +12.3% | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $337.48M | +100.8% | +47.9% | — |
| LTM Mar 2026 | $199.48M | +146.3% | +75.1% | — | |
| LTM Jun 2026 | $181.27M | +0.2% | -4.4% | 18.9% | |
| LTM Mar 2026 | $178.8M | +29.8% | +46.5% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $107.28M | +34.6% | +118.7% | 536.4% |
| LTM Mar 2026 | $56.41M | +34.0% | +29.0% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $39.17M | — | +20.7% | — |
| Peer median (excluding CMPS) | $153.38M | +34.3% | +29.0% | 285.1% | |
Competitors are the stored peer set for CMPS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.74M) | (91.51M) | (118.46M) | (155.12M) | (287.86M) |
| Depreciation & Amortization | 175K | 330K | 242K | 233K | 216K |
| Deferred Income Tax | 22K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.64M | 13.12M | 17.28M | 19.52M | 13.59M |
| Change in Working Capital | (6.64M) | (30.67M) | 3.48M | 11.72M | (14.28M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (163K) | 2.5M | 864K | 6.59M | 2.03M |
| Other Working Capital | (6.47M) | (33.16M) | 2.62M | 5.13M | (16.32M) |
| Other Non-Cash Items | 1.8M | 3.27M | 86K | 4.46M | 131.1M |
| Operating Cash Flow | (67.75M) | (105.45M) | (97.38M) | (119.19M) | (157.24M) |
| Capital Expenditures | (334K) | (596K) | (66K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 2K | 0 | 0 |
| Investing Cash Flow | (334K) | (596K) | (64K) | 0 | 0 |
| Debt Repayment | 0 | 0 | 29.59M | 0 | 0 |
| Common Stock Issued | 154.79M | 440K | 144.94M | 26.22M | 141.04M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.85M | 600K | (690K) | 37.61M | (328.83K) |
| Financing Cash Flow | 156.65M | 1.04M | 173.83M | 63.82M | 140.71M |
| Effect of Forex Changes | (5.58M) | (24.96M) | 867K | 194K | 1.05M |
| Net Change in Cash | 82.99M | (129.97M) | 77.26M | (55.17M) | (15.48M) |
| Free Cash Flow | (68.08M) | (106.05M) | (97.44M) | (119.19M) | (157.24M) |
COMPASS Pathways plc
NASDAQ:CMPS
Intrinsic Alpha fair value
Locked
Current Price
$8.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.